Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Nov;62(5):840–841. doi: 10.1038/bjc.1990.390

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours.

B Desoize 1, F Marechal 1, A Cattan 1
PMCID: PMC1971525  PMID: 2245178

Full text

PDF
840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark P. I., Slevin M. L. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet. 1987 Apr;12(4):223–252. doi: 10.2165/00003088-198712040-00001. [DOI] [PubMed] [Google Scholar]
  2. Cunningham D., McTaggart L., Soukop M., Cummings J., Forrest G. J., Stuart J. F. Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother. 1986;3(2):95–99. doi: 10.1007/BF02934560. [DOI] [PubMed] [Google Scholar]
  3. D'Incalci M., Rossi C., Zucchetti M., Urso R., Cavalli F., Mangioni C., Willems Y., Sessa C. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res. 1986 May;46(5):2566–2571. [PubMed] [Google Scholar]
  4. Desoize B., Garrett E. R. Superiority of perfusion over bolus administration in cancer chemotherapy: proposition of a compartmental model. Med Hypotheses. 1989 May;29(1):21–24. doi: 10.1016/0306-9877(89)90161-8. [DOI] [PubMed] [Google Scholar]
  5. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  6. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  7. Powis G. Anticancer drug pharmacodynamics. Cancer Chemother Pharmacol. 1985;14(3):177–183. doi: 10.1007/BF00258112. [DOI] [PubMed] [Google Scholar]
  8. Ratain M. J., Schilsky R. L., Choi K. E., Guarnieri C., Grimmer D., Vogelzang N. J., Senekjian E., Liebner M. A. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar;45(3):226–233. doi: 10.1038/clpt.1989.22. [DOI] [PubMed] [Google Scholar]
  9. Rodman J. H., Abromowitch M., Sinkule J. A., Hayes F. A., Rivera G. K., Evans W. E. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. J Clin Oncol. 1987 Jul;5(7):1007–1014. doi: 10.1200/JCO.1987.5.7.1007. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES